长程预防用量白葡奈氏菌片对中重度COPD患者机体免疫功能及生活质量的影响

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1320 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the effects of long-term prophylactic dose of Staphylococcus and Neisseria Tablets on immune function and life quality in patients with moderately severe COPD patients. Methods: Sixty patients with moderately severe COPD admitted to People’s Hospital of Quzhou between January 2016 to January 2017 were randomly divided into treatment group (n=30) and basic group (n=30). The treatment group was prescribed with Staphylococcus and Neisseria Tablets (two tablets twice daily, oral) for 3 months on the basis of routine treatment, while the basic group was given routine treatment only. After 3 months of treatment, analysis was made to compare the immune function and the life quality of these groups. The number of exacerbations was counted before and after treatment for 1 year. Meanwhile, 30 healthy people who came to our hospital for physical checkup in the same period were selected as healthy controls. Results: Compared with the control group, both the treatment group and the basic group had decreased levels of COPD CD3+, CD4+, CD4+/CD8+, NK cells, B cells, IgG, lgA, lgM, and increased levels of CD8+, HAD (P<0.05). The immune indices of the treatment group and the basic group did not show any significant difference (P>0.05). Patients in the treatment group did not report any obvious discomfort during the course of treatment. After the treatment, CD3+, CD4+, CD4+/CD8+, NK cells, B cells, IgG, lgA, FEV1 had increased, while CD8+, CAT, mMRC, HAD and the number of exacerbationshad decreased significantly (P<0.05). There was no significant difference in the level of IgM before and after treatment (P>0.05). Compared with the basic group, the frequency of upper respiratory tract infection and duration of the symptoms were significantly less in the treatment group (P<0.05). No obvious changes had been found in the indices of the basic group before and after treatment (P>0.05). Conclusion: The body’s immune function had declined in patients with moderately severe COPD. Long-term prophylactic dose of Staphylococcus and Neisseria Tablets was safe and effective, which can enhance the body’s immune function, reduce respiratory symptoms and improve life quality of the patients with moderately severe COPD.

Key words： pulmonary diseases, chronic obstructive Staphylococcus and Neisseria Tablets long-term immune function life quality

Received: 15 January 2018

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Xianbing
	LI Fang
	ZHENG Xiaoyan

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2018/V48/I9/676

[1] RABE K F, HURD S, ANZUETO A, et al. Global initiative for chronic obstructive lung disease[J]. Am J Respir Crit Care Med, 2007, 176(6): 532-555.
[2] BHAT T A, PANZICA L, KALATHIL S G, et al. Immune dysfunction in patients with chronic obstructive pulmonary disease[J]. Ann Am Thorac Soc, 2015, 12(Suppl2): S169-S175.
[3] BOZINOVSKI S, VLAHOS R, ANTHONY D, et al. COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link[J]. Br J Pharmacol, 2016, 173 (4): 635-648.
[4] 李宝林. 玉屏风散联用白葡奈氏菌片预防慢性支气管炎复发效果观察[J]. 中国临床研究, 2013, 5(7): 20-21.
[5] GOLD Executive Committee. Global slrategy for the diagnosis, matmgcment, and prevention of chronic obstmclivcpulmonarydisease (Revised 2011) [EB/OL]. http://www.goldc.com.2015-03-12.
[6] 叶维菲, 施寿康, 徐俊见, 等. 957例住院病人焦虑、抑郁障碍的研究[J]. 中国行为医学科学, 1995, 4(4): 198-222.
[7] 刘贤兵, 李芳, 陈晓萍, 等. 长期小剂量罗红霉素治疗对中重度COPD患者气道局部免疫的影响[J]. 温州医科大学学报, 2015, 45(10): 734-737.
[8] CARAMORI G, CASOLARI P, BARCZYK A, et al. COPD immunopathology[J]. Semin Immunopathol, 2016, 38(4): 497-515.
[9] POLVERINO F, COSIO B G, PONS J, et al. B Cell-activating factor. An orchestrator of lymphoid follicles in severe chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2015, 192(6): 695-705.
[10] 郑晓燕, 陈芳建, 吴芬芝. COPD患者外周血淋巴细胞亚群及其表面受体CXCR3的表达及相关分析[J]. 中国卫生检验杂志, 2015, 25(17): 2919-2921.
[11] KALATHIL S G, LUGADE A A, PRADHAN V, et al. T-regulatory cells and programmed death 1+T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2014, 190(1): 40-50.
[12] ZAGÓLSKI O, STREK P, KASPROWICZ A, et al. Effectiveness of polyvalent bacterial lysate and autovaccines against upper respiratory tract bacterial colonization by potential pathogens: A randomized study[J]. Med Sci Monit, 2015, 21: 2997-3002.
[13] TANDON M K, PHILLIPS M, WATERER G, et al. Oral Immunotherapy with inactivated NTHi reduces severity of acute exacerbations in severe COPD[J]. Chest, 2010, 137(4): 805-811.
[14] SHEN Y, YANG T, WANG T, et al. Elevated circulating cytotoxic T lymphocyte-associated antigen-4 levels are related to lung function and inflammation in chronic obstructive pulmonary disease[J]. Respirology, 2013, 18(5): 885-886.